TACR3 and digestive system disorder: These molecules were well tolerated, with side effects largely limited to mild gastrointestinal disorders and small transient rises in liver transaminases [37], suggesting that the repurposing of NK3R antagonists as pharmacological chaperones could be therapeutically viable.